Dr. Cheryl Greenberg, a pediatrician and geneticist, speaks to Dr. Suham Alexander about the clinical history and manifestations of HPP in her unique patient population in Winnipeg, MB. HPP is over-represented in the Mennonite population in Manitoba due to a “founder” mutation. Highlights HPP is categorized by age of onset: perinatal, infant, juvenile, adult (systemic forms) and odonto-hypophosphatasia (dental form). All patients with HPP must have a low level of alkaline phosphatase. There is a strong genetic basis for the various forms of HPP. There are more than 300 mutations described in the literature. However, one gene is responsible for ...

Dr. Aviv Ouanounou returns to Oasis Discussions to speak about drug therapy during pregnancy. This presentation is based on an article authored by Drs. Aviv Ouanounou and Dan Haas, from the University of Toronto, in the British Dental Journal in 2016. The article was also selected by the Royal College of Dental Surgeons of Ontario as a Practice Enhancement and Knowledge (PEAK*) resource for Ontario dentists. *The goal of PEAK is to provide Ontario dentists with key articles on a wide-range of clinical and non-clinical topics from dental literature around the world. Highlights Pregnancy is a special time in a ...

Highlights In the first segment of a 4-part series, Dr. Marc McKee introduces Oasis Discussions followers to a soft bone disease which also has a significant dental impact. Hypophosphatasia (HPP) is a very rare disease that has a prevalence of  approximately 1:100,000 live births.  Much progress has been made in recent years in understanding HPP, and in treating patients with this condition. HPP is a disease which negatively affects mineralization due to an increase in inhibitory pyrophosphate levels caused by decreased activity of an enzyme called tissue non-specific alkaline phosphatase (TNAP, TNSALP). This results in the inhibition of mineralization causing ...

The webinar is hosted by Dr. Tanya Gibson. The webinar explores the pathogenesis and risk factors of medication-related osteonecrosis of the jaw. As well, it looks at the recommended management strategies based on the clinical stage at the time of presentation. Participants will learn: the pathogenesis of MRONJ. risk factors for developing MRONJ. the clinical staging of MRONJ. management strategies for MRONJ. To register and attend the webinar, you can find more information here   Dr. Tanya Gibson DDS Tanya Marie Gibson, DDS, a native of Cleveland, Ohio, is an assistant professor at the University of Missouri Kansas City (UMKC) ...

Continuing our series of pharmacological topics, my conversation with Dr. Mark Donaldson was about premedication for dental procedures, in particular, about the management of orofacial infections with antimicrobials. It’s always a pleasure to host Dr. Donaldson on Oasis Discussions, and we hope that you will enjoy as well as benefit from this interview. I also would like to thank Dr. Donaldson for sharing the entire course with our viewers/readers.  Chiraz Guessaier, CDA Oasis Manager Resource Dr. Mark Donaldson: Premedication for Dental Procedures. Course Material. Please note that this material was initially developed for CE purposes. It is, however, presented here as ...

It’s always an honour to meet with Dr. Mark Donaldson, Pharmacologist and senior Executive Director at Vizient Inc. Part of our monthly conversations, Mark spoke about the three drug classes that every dental professional should know: antimicrobials, analgesics, and local anesthetics. I hope you find the interview informative.  Chiraz Guessaier, CDA Oasis Manager Highlights Oral healthcare professionals (OHCPs) are routinely involved with the selection and prescription of medications for their patients. This course is designed to help them become better-informed prescribers of the top three drug classes employed in dentistry: antibiotics, analgesics, and local anesthetics. Patient safety is the number ...

Drs. Deborah Saunders and Joel Epstein return to Oasis Discussions to discuss a third complication that occurs during cancer therapy and beyond, xerostomia. Xerostomia affects speech, chewing, swallowing, taste and overall nutrition which may negatively affect overall treatment and patient outcomes during therapy. Xerostomia is not related to aging as much as it reflects the use of medications that result in dry mouth. See also: Oral Care in Cancer Therapy Part 1: Oral Care Pre-Head & Neck Cancer TreatmentOral Care in Cancer Therapy Part 2: Oral Care During Cancer Therapy Functions of Saliva Antimicrobial activity Control of pH Removal of ...

My interview with Dr. Peter Jacobsen went by in a flash! His sense of humor, light-delivery approach, and lively style leaves you glued to the screen, wanting to learn more about the topic presented. Dr. Jacobsen joined me to speak about his upcoming lecture at #ASM150 titled: Fighting Dental Disease: Drugs, Bugs and Prescription Products. Chiraz Guessaier, CDA Oasis Manager Highlights What are the first, second, third drugs of choice for dental infections? Which antifungals have the greatest risk of drug interactions? Are OTC aphthous ulcers medications effective? Can the newest antiviral drugs prevent herpes attacks? Do they put Ginkgo Biloba ...